Insider Trading Alert - AGN, CODE And WYNN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 21, 2014, 123 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $98.40 to $9,872,759.00.

Highlighted Stocks Traded by Insiders:

Allergan (AGN) - FREE Research Report

Hudson Dawn E who is Director at Allergan sold 4,200 shares at $126.35 on Feb. 21, 2014. Following this transaction, the Director owned 11,600 shares meaning that the stake was reduced by 26.58% with the 4,200-share transaction.

The shares most recently traded at $125.84, down $0.51, or 0.41% since the insider transaction. Historical insider transactions for Allergan go as follows:

  • 4-Week # shares sold: 118
  • 12-Week # shares sold: 118
  • 24-Week # shares sold: 5,118

The average volume for Allergan has been 2.4 million shares per day over the past 30 days. Allergan has a market cap of $37.8 billion and is part of the health care sector and drugs industry. Shares are up 12.59% year-to-date as of the close of trading on Friday.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. The stock currently has a dividend yield of 0.16%. The company has a P/E ratio of 26.7. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGN - FREE

TheStreet Quant Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Stock Observations; Reviewing Equities: Doug Kass' Views

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Teva's New CEO Brings This Secret Weapon

Will Allergan's Deal With Tribe Hold Up?

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)